Skip to main content

Sales Of Nerve Repair And Regeneration Devices Are Set To Increase At 11% CAGR Through 2026

 As per an in-depth industry analysis by Fact.MR, a market research and competitive intelligence provider, global demand for nerve repair and regeneration devices is expected to reach a valuation of US$ 12 billion by 2026, rising at a high CAGR of 11% over the forecast period (2022–2026).

  • Renerva is an innovative medical device start-up based in the U.S. that joined Cornell University’s McGovern Center life sciences business. Renerva is developing an over-the-counter nerve transplant product that could prevent individuals from suffering from permanent disability and improving an injectable gel to speed up the regeneration of damaged nerves.

By Product :

  • Neurostimulation & Neuromodulation Devices
  • Biomaterials

 

By Application :

  • Neurostimulation & Neuromodulation Surgeries
  • Neurorrhaphy
  • Nerve Grafting
  • Stem Cell Therapy

 

By End User :

  • Hospitals
  • Clinics
  • Ambulatory Surgery Centers

 

By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

  • Scientists at the Mayo Clinic are developing a cell-based treatment for the neurodegenerative condition amyotrophic lateral sclerosis. They hope to do this by using a patient’s own adipose-derived mesenchymal stem cells, modifying them in a lab, and then reintroducing them into the person’s body.

  • Baxter
  • Polyganics B.V.
  • Nevro
  • Stryker
  • Abbott Laboratories
  • AxoGen, Inc.
  • Boston Scientific Corporation
  • Integra LifeSciences Corporation
  • LivaNova, PLC

  • Global nerve repair and regeneration market to reach valuation of US$ 12 billion by 2026.
  • Market in Canada expected to rise at 9% CAGR from 2022 to 2026.
  • Market in Germany set to expand at 9.5% CAGR over the forecast period.
  • Demand for neurostimulation & neuromodulation devices projected to rise at 9.5% CAGR through 2026.

Comments